---
title: "688298.SH (688298.SH) — Related News"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/688298.SH/news.md"
symbol: "688298.SH"
name: "688298.SH"
parent: "https://longbridge.com/en/quote/688298.SH.md"
datetime: "2026-05-21T13:49:39.699Z"
locales:
  - [en](https://longbridge.com/en/quote/688298.SH/news.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/688298.SH/news.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/688298.SH/news.md)
---

# 688298.SH (688298.SH) — Related News

### [Orient Biotech: Multiple products have obtained medical device product registration certificates](https://longbridge.com/en/news/287196168.md)
*2026-05-21T10:01:02.000Z*
> Orient Biotech announced that the company and its subsidiaries Healgen Scientific LLC and Hangzhou Danwei Biotechnology 

### [Orient Biotech: Subsidiary has hantavirus antibody detection reagents, but has not yet obtained overseas registration certificate](https://longbridge.com/en/news/285703958.md)
*2026-05-08T10:11:29.000Z*
> In response to recent market concerns regarding the Hantavirus testing products, Orient Biotech stated that its subsidia

### [Orient Biotech's net loss attributable to the parent company for the year 2025 is 564 million yuan](https://longbridge.com/en/news/277160489.md)
*2026-02-27T07:58:26.000Z*
> Orient Biotech disclosed in its 2025 performance preliminary report that the company achieved total operating revenue of

### [Orient Biotech: Stock price has long been below net asset value, launching a valuation enhancement plan](https://longbridge.com/en/news/275285972.md)
*2026-02-09T08:27:52.000Z*
> Orient Biotech announced that from October 9, 2024, to October 8, 2025, if the company's stock closes below its net asse

### [As the pandemic benefits wane, Orient Biotech faces three consecutive losses after a windfall, entangled in lawsuits and encountering obstacles in going overseas](https://longbridge.com/en/news/274902509.md)
*2026-02-05T02:26:47.000Z*
> Orient Biotech expects a net loss of 523 million yuan attributable to the parent company in 2025 due to the decline of p

### [Orient Biotech issues a profit warning, expecting a net loss attributable to shareholders of 523 million yuan for the year 2025](https://longbridge.com/en/news/274149121.md)
*2026-01-29T12:23:04.000Z*
> Orient Biotech released a preliminary announcement of expected losses for the 2025 annual performance, estimating a net 

### [](https://longbridge.com/en/news/273649643.md)
*2026-01-26T05:15:09.000Z*
> The A-share biopharmaceutical sector continues to strengthen, with Maccura, Hybribio Biotech, and KHB hitting the daily